Pricing, reimbursement and access
Refine Search
Pharmaceutical
Efforts to combat antimicrobial resistance (AMR) are gaining momentum in Europe, with the introduction of innovative measures to drive the development of new antimicrobials. 25 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Pharmaceutical
Johnson & Johnson has taken legal action to defend a contentious rebate initiative, filing a lawsuit in the US District Court for the District of Columbia. 15 November 2024
Biotechnology
Sanofi has announced that the UK's health technology assessor will conduct a new review of its Sarclisa (isatuximab) combo therapy for relapsed or refractory multiple myeloma. 13 November 2024
Pharmaceutical
The US trade group Pharmaceutical Research and Manufacturers of America (PhRMA) today launched new advertisements urging Congress to make sure savings on medicines go to patients, not middlemen. 11 November 2024
Pharmaceutical
Danish patients are being offered fewer innovative treatments than Norwegians and Swedes, a new estimate from the Danish Medicines Council shows. 11 November 2024
Pharmaceutical
UK pharma major AstraZeneca today announced that the National Institute for Health and Care Excellence (NICE) published its final draft guidance (FDG) recommending Wainzua (eplontersen) as a treatment option for hereditary transthyretin-related amyloidosis (ATTR) in adults with stage 1 or stage 2 polyneuropathy across England and Wales. 29 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Pharmaceutical
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for breast cancer, providing a boost to Novartis' Kisqali (ribociclib). 24 October 2024
Biotechnology
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s (NYSE: LLY) Kisunla (donanemab) for people in Britain with mild cognitive impairment or those in the early stages of Alzheimer’s disease. 23 October 2024
Pharmaceutical
The US Department of Health and Human Services (HHS), through the Office of Assistant Secretary for Planning and Evaluation (ASPE), yesterday released new data showing that nearly 1.5 million people with Medicare Part D saved nearly $1 billion in out-of-pocket prescription drugs costs in the first half of 2024 because of the Biden-Harris Administration’s Inflation Reduction Act. 23 October 2024
Pharmaceutical
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC, the drug’s French developer Ipsen announced today. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Pharmaceutical Research and Manufacturers of America (PhRMA) says it has submitted comments to the Office of the United States Trade Representative (USTR) to inform the agency’s 2025 National Trade Estimate (NTE) Report on Foreign Trade Barriers. 21 October 2024
Pharmaceutical
“The new key figures from the NZa show that Dutch expenditure on expensive medicines remains stable,” says Mark Kramer, chairman of the Association of Innovative Medicines (VIG), adding: “That is good news from a social perspective.” 21 October 2024
Pharmaceutical
The Danish Medicines Council (Medicinrådet), responsible for evaluating and recommending new treatments for Denmark’s healthcare system, is facing a significant increase in processing times. 14 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Biosimilars
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States. 11 October 2024
Biotechnology
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Generics
CMS released a Request for Information (RFI) and a sample list of prescription drugs that the agency preliminarily intends to include under the proposed Medicare $2 Drug List Model. 10 October 2024
Generics
Budget Perspectives 2012, a paper published last week by the Economic and Social Research Institute (ESRI), suggests high rates of spending on pharmaceuticals in Ireland could be attributable to the low penetration of generic drugs in the Irish market. According to the report, OECD data shows per capita spending in 2009 on pharmaceuticals in Ireland - at 1.7% of Gross Domestic Product (GDP) - was fourth highest among OECD countries after the USA, Canada and Greece. 24 October 2011
Pharmaceutical
Data from eight countries shows that using Anglo-Swedish drug major AstraZeneca's (LSE: AZN) Brilique/Brilinta (ticagrelor) plus aspirin to treat acute coronary syndrome (ACS) patients for one year is associated with cost-savings, gain in quality-adjusted life years, and life-years gained compared to treatment with both generic and branded clopidogrel plus aspirin. 24 October 2011
Pharmaceutical
Treating patients with the new blood thinning medication dabigatran (German independent drug major Boehringer Ingelheim's recently approved Pradaxa), instead of warfarin results in significantly higher per patient costs and higher net costs per stroke avoided, according to a new study by US pharmacy benefit manager Prime Therapeutics. 20 October 2011
Pharmaceutical
US President Barack Obama and some members of Congress have proposed requiring that prescription drug manufacturers pay rebates to the federal government for drugs dispensed to Medicaid/Medicare dual-eligible beneficiaries and other low-income seniors through the Medicare Part D program. 20 October 2011
Pharmaceutical
The UK drugs watchdog the National Institute of Health and Clinical Excellence (NICE) today published a preliminary recommendations for National Health Service use of US drug major Eli Lilly's (NYSE: LLY) Bydureon (exenatide prolonged release suspension for injection) in triple therapy regimens as a treatment option for people with type 2 diabetes, when control of blood glucose remains or becomes inadequate (HbA1c of 7.5% or above, or other higher level agreed with the individual), and the person has: 18 October 2011
Pharmaceutical
US Senator Herb Kohl (Democrat, Wisconsin), Chairman of the US Senate Special Committee on Aging, last week introduced legislation seeking a wide range of drug cost cuts, including a proposal to require drug manufacturers to provide Medicare Part B with the same discounts Medicaid receives, saying his: 'Prescription Drug Cost Reduction Act provides a number of opportunities to significantly reduce the cost of health care without pushing those costs onto consumers or limiting access to care.' 17 October 2011
Pharmaceutical
A US Congressional letter was sent to members of the Joint Select Committee on Deficit Reduction from more than 60 bipartisan members of Congress last Friday, urging the committee to reject a proposed $3 billion cut to cancer drugs that, if enacted, according to the letter, would adversely affect cancer care in the USA. 16 October 2011
Pharmaceutical
UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued new draft guidance which recommends against the use of US drug major Bristol-Myers Squibb's (NYSE: BMY) Yervoy (ipilimumab) for advanced malignant melanoma in people who have received prior chemotherapy. The draft guidance has been issued for consultation; it has not been issued to the National Health Service. 14 October 2011
Generics
Meeting yesterday in Warsaw, Poland, the European Generic medicines Association's (EGA) board announced the election of Gudbjorg Edda Eggertsdottir as its new president. Ms Eggertsdottir has been active in the generic medicines industry for over 30 years, witnessing the many challenges it has already faced on its way to becoming an essential part of the global healthcare offering. 12 October 2011
Pharmaceutical
The drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today opened a consultation on draft guidance which provisionally recommends the use of Swiss drug major Roche's (ROG: SIX) RoActemra (tocilizumab) at additional stages in treating rheumatoid arthritis. 7 October 2011
Pharmaceutical
Despite an increase in the number of approved orphan drugs in Europe, the overall growth in cost of these medicines as a proportion of total pharmaceutical expenditure is likely to be sustainable over the next decade, according to the results of a new analysis published in the Orphanet Journal of Rare Diseases. 6 October 2011
Pharmaceutical
The annual cost of brain disorders in Europe has soared to 798 billion euros ($1,070 billion) in what a new study commissioned by the European Brain Council (EBC), describes as a social, political and financial 'ticking bomb.' 5 October 2011
Pharmaceutical
The German reimbursement body, the Federal Joint Committee (G-BA), has published the Institute for Quality and Efficiency in Healthcare (IQWiG) preliminary assessment report regarding the medical benefit of Anglo-Swedish drug major AstraZeneca's (LSE: AZN) clot buster Brilique (ticagrelor; also sold as Brilinta). 5 October 2011
Pharmaceutical
More than 160,000 Australians per year will benefit from the Australian Government's decision to provide subsidised access to 48 medicines, including treatments for serious heart conditions including heart failure in infants and children, rare but serious infections like tuberculosis, and cancer. 3 October 2011
Pharmaceutical
Access to expensive medicines is becoming increasingly difficult in Portuguese public hospitals, while savings with retail pharmacy expenditure are expected to be better than projections in the Memorandum of Understanding (MoU) deal signed by the government, according to a research note released its author, Tania Rodrigues, an analyst at IHS Global Insight. 30 September 2011
Pharmaceutical
UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) this morning issued new draft guidance, which is now open to consultation, not recommending the use of French drug major Sanofi's Jevtana (cabazitaxel), in combination with prednisone or prednisolone as a second line treatment for prostate cancer. But came out in favor of Denmark-based ALK-Abello's (ALKB: DC) Pharmalgen. 30 September 2011
Pharmaceutical
An analysis of cervical-cancer vaccine has shown that Merck & Co's (NYSE: MRK) Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] Vaccine, Recombinant), is more cost-effective than Cervarix (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant), a rival product from GlaxoSmithKline (LSE: GSK). The review was conducted by researchers from the UK's Health Protection Agency, led by Mark Jit, which was posted on the British Medical Journal web site. 29 September 2011
Pharmaceutical
Claims that prescription drug costs are at the root of Canada's health spending crisis are unfounded and not supported by any proof, concludes a new report by the Fraser Institute, Canada's leading public policy think-tank. 28 September 2011
Pharmaceutical
Recent government drug pricing reforms have cost the German pharmaceutical industry billions of euros, according to the latest annual overview of the pharma market from industry association BPI. The government imposed a three-year price moratorium last year and hiked the discount that manufacturers are obliged to offer state health insurers from 6% to 16%. 27 September 2011
Generics
The multi-year uptrend in drug expenditure by Germany's health insurers could be ending, according to the latest Arzneiverordnungs Report (AVR), an annual study of the drug market. The report is published by the Scientific Institute of the AOK, Germany's biggest health insurance fund, and based on 791 million prescriptions by over 140,000 doctors. 23 September 2011
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze